Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 20/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

2 recruiting3 with results

Enrollment Performance

Analytics

N/A

3(42.9%)

Phase 4

3(42.9%)

Phase 2

1(14.3%)

7Total

N/A(3)

Phase 4(3)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05937854Phase 2Recruiting

Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

Role: collaborator

NCT03568630Recruiting

Blood Markers of Early Pancreas Cancer

Role: collaborator

NCT00871637Completed

Airway Macrophages and Sputum Milieu in Adult Subjects With Airflow Obstruction

Role: collaborator

NCT00548652Not ApplicableCompleted

Role of Apathy in the Effectiveness of Weight Loss Interventions

Role: lead

NCT01271244Phase 4Completed

Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder

Role: lead

NCT02382042Not ApplicableUnknown

Intensive Referral Intervention to Improve Substance Use Disorder Treatment Outcomes Among Rural and Highly Rural Veterans

Role: lead

NCT00726713Phase 4Completed

Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN)

Role: collaborator

NCT01420575Not ApplicableTerminated

Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia

Role: lead

NCT01012830Phase 4Unknown

Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia

Role: lead

All 9 trials loaded